EDIT Editas Medicine Inc

Price (delayed)

$32.80

Market cap

$2.22B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.21

Enterprise value

$1.9B

Sector: Healthcare
Industry: Biotechnology

Highlights

EDIT's equity has soared by 172% year-on-year and by 62% since the previous quarter
Editas Medicine's quick ratio has surged by 62% YoY and by 40% QoQ
EDIT's EPS is up by 20% year-on-year but it is down by 12% since the previous quarter
Editas Medicine's net income has decreased by 16% QoQ but it has increased by 5% YoY
The debt has grown by 11% from the previous quarter and by 6% YoY

Key stats

What are the main financial stats of EDIT
Market
Shares outstanding
67.83M
Market cap
$2.22B
Enterprise value
$1.9B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.46
Price to sales (P/S)
23.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
20.75
Earnings
Revenue
$91.51M
EBIT
-$136.16M
EBITDA
-$131.84M
Free cash flow
-$180.32M
Per share
EPS
-$2.21
Free cash flow per share
-$2.73
Book value per share
$9.47
Revenue per share
$1.39
TBVPS
$11.82
Balance sheet
Total assets
$780.29M
Total liabilities
$142.3M
Debt
$28.89M
Equity
$638M
Working capital
$568.31M
Liquidity
Debt to equity
0.05
Current ratio
9.88
Quick ratio
9.78
Net debt/EBITDA
2.47
Margins
EBITDA margin
-144.1%
Gross margin
100%
Net margin
-147.5%
Operating margin
-158.6%
Efficiency
Return on assets
-20.7%
Return on equity
-28.4%
Return on invested capital
-45%
Return on capital employed
-19%
Return on sales
-148.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EDIT stock price

How has the Editas Medicine stock price performed over time
Intraday
4.83%
1 week
-5.37%
1 month
-16.88%
1 year
19.58%
YTD
-53.22%
QTD
-21.9%

Financial performance

How have Editas Medicine's revenue and profit performed over time
Revenue
$91.51M
Gross profit
$91.51M
Operating income
-$145.11M
Net income
-$134.98M
Gross margin
100%
Net margin
-147.5%
EDIT's operating margin has surged by 75% year-on-year but it is down by 7% since the previous quarter
The net margin has soared by 75% YoY but it has contracted by 15% from the previous quarter
Editas Medicine's net income has decreased by 16% QoQ but it has increased by 5% YoY
EDIT's operating income is down by 8% since the previous quarter but it is up by 7% year-on-year

Growth

What is Editas Medicine's growth rate over time

Valuation

What is Editas Medicine stock price valuation
P/E
N/A
P/B
3.46
P/S
23.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
20.75
EDIT's EPS is up by 20% year-on-year but it is down by 12% since the previous quarter
EDIT's equity has soared by 172% year-on-year and by 62% since the previous quarter
EDIT's P/B is 40% below its last 4 quarters average of 5.8 and 36% below its 5-year quarterly average of 5.4
The P/S is 67% less than the 5-year quarterly average of 72.1 and 35% less than the last 4 quarters average of 36.2

Efficiency

How efficient is Editas Medicine business performance
EDIT's return on sales has surged by 76% year-on-year but it is down by 14% since the previous quarter
The ROE has soared by 55% YoY and by 8% from the previous quarter
EDIT's return on invested capital is up by 44% year-on-year and by 3.8% since the previous quarter
Editas Medicine's ROA has increased by 38% YoY but it has decreased by 2.5% from the previous quarter

Dividends

What is EDIT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EDIT.

Financial health

How did Editas Medicine financials performed over time
EDIT's total assets has soared by 67% YoY and by 36% QoQ
Editas Medicine's quick ratio has surged by 62% YoY and by 40% QoQ
The debt is 95% less than the equity
EDIT's equity has soared by 172% year-on-year and by 62% since the previous quarter
The company's debt to equity has shrunk by 58% YoY and by 29% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.